|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 403/14 | (2006.01) |
| A61K 31/4192 | (2006.01) | ||
| A61P 25/00 | (2006.01) |
| (11) | Number of the document | 3077390 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14824108.6 |
| Date of filing the European patent application | 2014-12-02 | |
| (97) | Date of publication of the European application | 2016-10-12 |
| (45) | Date of publication and mention of the grant of the patent | 2017-09-13 |
| (46) | Date of publication of the claims translation | 2017-11-27 |
| (86) | Number | PCT/IB2014/066509 |
| Date | 2014-12-02 |
| (87) | Number | WO 2015/083071 |
| Date | 2015-06-11 |
| (30) | Number | Date | Country code |
| PCT/IB2013/0605 | 2013-12-03 | WO |
| (72) |
BOSS, Christoph, CH
BROTSCHI, Christine, CH
GUDE, Markus, CH
HEIDMANN, Bibia, CH
SIFFERLEN, Thierry, CH
VON RAUMER, Markus, CH
WILLIAMS, Jodi T., CH
|
| (73) |
Idorsia Pharmaceuticals Ltd,
Hegenheimermattweg 91, 4123 Allschwil,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | (S)-(2-(6-chlor-7-metil-1H-benzo[D]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2H-1,2,3-triazol-2-il)fenil)metanono druskos kristalinė forma, kaip oreksino receptoriaus antagonistas |
| CRYSTALLINE SALT FORM OF (S)-(2-(6-CHLORO-7-METHYL-1H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1-YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AS OREXIN RECEPTOR ANTAGONIST |
| Payment date | Validity (years) | Amount | |
| 2024-11-22 | 11 | 289.00 EUR |
| 2025-12-02 |